The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
Author:
Publisher
Elsevier BV
Subject
Pharmacology,General Medicine
Reference78 articles.
1. Molecular therapies and precision medicine for hepatocellular carcinoma;Llovet;Nat. Rev. Clin. Oncol.,2018
2. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B;Papatheodoridis;J. Hepatol.,2020
3. Reply to: “detecting microvascular invasion in HCC with contrast-enhanced MRI: is it a good idea?”;Lee;J. Hepatol.,2018
4. Time to recurrence, but not recurrence-free survival, should be the endpoint used to predict early recurrence after HCC resection;Yan;J. Hepatol.,2019
5. Combination set to transform HCC therapy;Romero;Nat. Rev. Clin. Oncol.,2020
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma;International Immunopharmacology;2024-10
2. Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis;ImmunoTargets and Therapy;2024-06
3. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus;World Journal of Gastroenterology;2024-02-28
4. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis;Frontiers in Oncology;2024-02-16
5. Combined transarterial therapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors in unresectable hepatocellular carcinoma;2024-02-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3